Shares of Emergent Biosolutions Inc (NYSE:EBS) have received a consensus rating of “Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $65.71.
EBS has been the topic of a number of research analyst reports. Chardan Capital boosted their target price on Emergent Biosolutions from $60.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Zacks Investment Research downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Cantor Fitzgerald set a $62.00 target price on Emergent Biosolutions and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Cowen restated a “hold” rating and issued a $49.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, August 29th. Finally, Wells Fargo & Co set a $61.00 target price on Emergent Biosolutions and gave the stock a “hold” rating in a research note on Friday, August 10th.
Shares of EBS opened at $70.31 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.52 and a quick ratio of 4.29. The company has a market cap of $3.24 billion, a price-to-earnings ratio of 36.52, a P/E/G ratio of 1.35 and a beta of 1.27. Emergent Biosolutions has a 52 week low of $36.38 and a 52 week high of $69.53.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.07). Emergent Biosolutions had a return on equity of 12.89% and a net margin of 14.19%. The company had revenue of $173.70 million for the quarter, compared to the consensus estimate of $185.16 million. During the same period in the prior year, the firm posted $0.73 earnings per share. The business’s revenue for the quarter was up 16.3% on a year-over-year basis. Analysts expect that Emergent Biosolutions will post 2.36 EPS for the current year.
In related news, Chairman Fuad El-Hibri sold 36,318 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $55.98, for a total value of $2,033,081.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Adam Havey sold 22,996 shares of the company’s stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $61.06, for a total value of $1,404,135.76. Following the completion of the transaction, the executive vice president now owns 36,079 shares in the company, valued at approximately $2,202,983.74. The disclosure for this sale can be found here. In the last quarter, insiders sold 195,701 shares of company stock worth $11,819,391. 13.40% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its stake in Emergent Biosolutions by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 755,948 shares of the biopharmaceutical company’s stock valued at $38,167,000 after purchasing an additional 16,801 shares during the last quarter. GAM Holding AG purchased a new stake in shares of Emergent Biosolutions during the second quarter worth $500,000. Northern Trust Corp lifted its position in shares of Emergent Biosolutions by 11.3% during the second quarter. Northern Trust Corp now owns 1,150,184 shares of the biopharmaceutical company’s stock worth $58,072,000 after acquiring an additional 117,098 shares in the last quarter. Summit Global Investments lifted its position in shares of Emergent Biosolutions by 9.4% during the second quarter. Summit Global Investments now owns 12,800 shares of the biopharmaceutical company’s stock worth $646,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Sei Investments Co. lifted its position in shares of Emergent Biosolutions by 33.0% during the second quarter. Sei Investments Co. now owns 5,106 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 1,268 shares in the last quarter. Institutional investors and hedge funds own 82.76% of the company’s stock.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Further Reading: Dollar Cost Averaging
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.